Theravance Biopharma

Focus: Theravance Biopharma is a small-molecule focused pharmaceutical company headquartered in South San Francisco, generating 100% of revenue from its marketed antibiotic VIBATIV. The company maintains a diversified pipeline spanning respiratory, immunology, infectious diseases, gastroenterology, and nephrology.

Respiratory Immunology Infectious Diseases Gastroenterology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Theravance Biopharma

AI assessmentNot Hiring

No open roles listed right now. Follow Theravance Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

VIBATIV

Bacterial pneumonia, staphylococcal skin infections, bacteremia

$0.782M Part D

Peak

Only marketed product generating 100% of company revenue; mature antibiotic with narrow Part D spending indicating limited growth trajectory.

Products & Portfolio (1)

Help build intelligence for Theravance Biopharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

albuterol sulfate

COVID-19

N/A

Clinical Trials (1)

NCT04681079Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19

N/A

Nezulcitinib

Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)

Phase 1

Clinical Trials (1)

NCT05091723TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation

Phase 1

Telavancin

Healthy

Phase 1

Clinical Trials (1)

NCT02753855Pharmacokinetics of Telavancin in Normal and Obese Subjects

Phase 1

GSK961081 15mcg SD

Pulmonary Disease, Chronic Obstructive

Phase 1

TD-9855

ADHD

Phase 1

Clinical Trials (1)

NCT01924143TD-9855 Mass Balance Study

Phase 1

TD-1473

Ulcerative Colitis, Active Moderate

Phase 1

Clinical Trials (1)

NCT02818686TD-1473 for Active Ulcerative Colitis (UC)

Phase 1

TD-3504

Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects

Phase 1

Clinical Trials (1)

NCT03103412TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

Phase 1

TD-1473

Inflammatory Bowel Disease

Phase 1

Clinical Trials (1)

NCT03555617Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

Phase 1

TD-6450

Hepatitis C

Phase 1

Clinical Trials (1)

NCT02022306TD-6450 SAD and MAD in Healthy Subjects

Phase 1

TD-1058

Idiopathic Pulmonary Fibrosis (IPF)

Phase 1

Clinical Trials (1)

NCT04589260TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis

Phase 1

Ampreloxetine

Symptomatic Neurogenic Orthostatic Hypertension

Phase 1

Clinical Trials (1)

NCT04200573Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855

Phase 1

TD-8236

Asthma

Phase 1

Clinical Trials (1)

NCT03652038Single and Multiple Ascending Dose Study of TD-8236 by Inhalation

Phase 1

Ampreloxetine <Dose A>

Symptomatic Neurogenic Orthostatic Hypertension

Phase 1

Clinical Trials (1)

NCT04688632Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

Phase 1

TD-6450

Hepatitis C

Phase 1

Clinical Trials (1)

NCT02116543TD-6450 MAD Study in HCV Infected Subjects

Phase 1

TD-1211 Dose 1

Constipation

Phase 1

Clinical Trials (1)

NCT01655771TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects

Phase 1

TD-1473 - Dose A

Inflammatory Bowel Diseases

Phase 1

Clinical Trials (1)

NCT03750565Multiple Dose Ethnobridging PK Study in Healthy Subjects

Phase 1

Velusetrag

Alzheimer's Disease

Phase 1

TD-4208

Chronic Obstructive Pulmonary Disease (COPD)

Phase 1

Clinical Trials (1)

NCT02772159TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

Phase 1

TD-8954

Gastrointestinal Motility Disorder

Phase 1

Clinical Trials (1)

NCT01644240A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects

Phase 1

TD-1473 oral capsule

Intestinal Disorders

Phase 1

Clinical Trials (1)

NCT03408470TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

Phase 1

GSK961081

Pulmonary Disease, Chronic Obstructive

Phase 1

TD-0714

Healthy

Phase 1

Clinical Trials (1)

NCT02639078Single Ascending Dose Study of TD-0714 in Healthy Subjects

Phase 1

GSK961081

Pulmonary Disease, Chronic Obstructive

Phase 1

TD-0714

Healthy Adults, Elderly Subjects

Phase 1

Clinical Trials (1)

NCT02709928Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects

Phase 1

TD-1607

Infections

Phase 1

Clinical Trials (1)

NCT01949103TD-1607 MAD Study in Healthy Subjects

Phase 1

TD-1211 IV [C14]

OIC

Phase 1

Clinical Trials (1)

NCT01702194TD-1211 IV/Oral Mass Balance Study

Phase 1

TD-4208

Renal Impairment

Phase 1

Clinical Trials (1)

NCT02578082Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment

Phase 1

TD-9855

Drug Drug Interaction (DDI)

Phase 1

Clinical Trials (1)

NCT03432793Drug-Drug Interaction (DDI) Study for TD-9855

Phase 1

TD-1473 [Tablet A]

Intestinal Disorder

Phase 1

Clinical Trials (1)

NCT04587713Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects

Phase 1

TD-1211

Healthy

Phase 1

Clinical Trials (1)

NCT01568411A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211

Phase 1

TD-1607

Serious Infections Due to Known or Suspected Gram-positive Pathogens

Phase 1

Clinical Trials (1)

NCT01791049TD-1607 SAD Study in Healthy Subjects

Phase 1

TD-1439

Healthy Adults, Elderly Subjects

Phase 1

Clinical Trials (1)

NCT02954263Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects

Phase 1

TD-1439

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT02903095Single Ascending Dose Study of TD-1439 in Healthy Subjects

Phase 1

[14C]-GSK961081 solution for IV infusion

Pulmonary Disease, Chronic Obstructive

Phase 1

TD-5202

Healthy

Phase 1

Clinical Trials (1)

NCT04044339Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects

Phase 1

TD-1473 for SAD

Healthy

Phase 1

Clinical Trials (1)

NCT02657122SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects

Phase 1

TD-4208

Hepatic Impairment

Phase 1

Clinical Trials (1)

NCT02581592Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment

Phase 1

TD-4208 175 mcg

Cardiac Repolarization in Healthy Subjects

Phase 1

Clinical Trials (1)

NCT02820311Thorough QT (TQT) Study of TD-4208 in Healthy Subjects

Phase 1

TD-0903

Acute Lung Injury (ALI) Associated With COVID-19

Phase 1

Clinical Trials (1)

NCT04350736First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19

Phase 1

TD-8954

Enteral Feeding Intolerance

Phase 1/2

TD-1211

Healthy

Phase 1/2

Clinical Trials (1)

NCT01040637A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation

Phase 1/2

Velusetrag

Gastroparesis

Phase 2

TD-1211

Opioid-induced Constipation (OIC)

Phase 2

Clinical Trials (1)

NCT01333540A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation

Phase 2

Placebo

Chronic Obstructive Pulmonary Disease, COPD

Phase 2

Clinical Trials (1)

NCT03064113Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

TD-9855 Group 1

Fibromyalgia

Phase 2

Clinical Trials (1)

NCT01693692Phase 2 Study of TD-9855 to Treat Fibromyalgia

Phase 2

TD-1211

Opioid Induced Constipation

Phase 2

Clinical Trials (1)

NCT01401985A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)

Phase 2

TD-4208

Chronic Obstructive Pulmonary Disease

Phase 2

Clinical Trials (1)

NCT02109172A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

TD-9855

Attention-Deficit/Hyperactivity Disorder

Phase 2

Clinical Trials (1)

NCT01458340A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 2

TD-1211

Opioid Induced Constipation

Phase 2

Clinical Trials (1)

NCT01459926A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation

Phase 2

Placebo

Crohn's Disease

Phase 2

Clinical Trials (1)

NCT03635112Efficacy and Safety of TD-1473 in Crohn's Disease

Phase 2